Inhibrx Inc
NASDAQ:INBX
Inhibrx Inc
NASDAQ:INBX
Price:
34.04 USD
Market Closed
Updated:
May 1, 2024
Section:
Relative Value
The Relative Value of one
INBX
stock under the Base Case scenario is
25.84
USD.
Compared to the current market price of 34.04 USD,
Inhibrx Inc
is
Overvalued by 24%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
INBX
Relative Value
Base Case
25.84
USD
Overvaluation 24%
Valuation Multiples
Multiples Across Competitors
INBX Competitors Multiples
Inhibrx Inc Competitors
Inhibrx Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Inhibrx Inc
NASDAQ:INBX
|
1.6B USD | 895.8 | -6.7 | -7.1 | -7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
288.7B USD | 5.3 | 59.9 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
147.9B USD | 5.2 | 22 | 16.4 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103B USD | 10.4 | 28.5 | 22.8 | 23.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.5B USD | 7.5 | 24.9 | 16.5 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.6B AUD | 6.1 | 34.7 | 21.1 | 26.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.7B USD | 6.1 | -8.8 | -9.3 | -7.9 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 27 | 14.6 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
